Anzeige
Mehr »
Donnerstag, 15.05.2025 - Börsentäglich über 12.000 News
Verpasst du gerade die Buffett-Aktie der neuen Generation?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QJRU | ISIN: US30233G2093 | Ticker-Symbol: PV3B
Tradegate
15.05.25 | 15:49
4,920 Euro
0,00 % 0,000
Branche
Pharma
Aktienmarkt
NASDAQ Biotech
1-Jahres-Chart
EYEPOINT PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
EYEPOINT PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,7975,01017:00
4,7925,00417:00

Aktuelle News zur EYEPOINT PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.05.Eyepoint projects DURAVYU Phase 3 enrollment completion by H2 2025 amid strong clinical trial momentum6
07.05.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
06.05.A Peek at EyePoint Pharmaceuticals' Future Earnings4
06.05.EyePoint Pharmaceuticals Q1 2025 Earnings Preview6
30.04.EyePoint Pharmaceuticals, Inc.: EyePoint to Report First Quarter 2025 Financial Results on May 7, 20255
16.04.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)103WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
► Artikel lesen
17.03.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)290WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of...
► Artikel lesen
06.03.Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews6
EYEPOINT PHARMACEUTICALS Aktie jetzt für 0€ handeln
06.03.EyePoint Pharmaceuticals, Inc. - 10-K, Annual Report-
06.03.H.C. Wainwright maintains EyePoint stock Buy rating, $22 target3
05.03.EyePoint Pharmaceuticals, Inc. Q4 Loss Increases, Misses Estimates11
04.03.EyePoint Pharmaceuticals Q4 2024 Earnings Preview7
04.03.EyePoint Pharmaceuticals, Inc. - 8-K, Current Report1
17.02.EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)180WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients...
► Artikel lesen
05.02.EyePoint Pharmaceuticals Stock Gains 3% After Positive Phase 2 Trial Results6
05.02.EyePoint stock jumps 10% on Duravyu study results2
05.02.TD Cowen maintains EyePoint stock Buy rating, $20 target3
05.02.EyePoint's decline following positive data makes no sense, says analyst7
05.02.Pre-market Movers: Pasithea Therapeutics, EyePoint Pharmaceuticals, Samfine Creation, Volcon, Adicet Bio651SUNNYVALE (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Pasithea Therapeutics Corp. (KTTA) is up over...
► Artikel lesen
05.02.Aktien von EyePoint Pharmaceuticals brechen trotz positiver Studienergebnisse ein15
Seite:  Weiter >>
44 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1